Drugs / PJ009
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06523101 | Feb → May 2023 | short bowel syndrome | Chongqing Peg-Bio Biopharm Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06512584 | Sep 2024 → Mar 2026 overdue | short bowel syndrome | Chongqing Peg-Bio Biopharm Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PJ009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06523101 ↗ |
| Route | Subcutaneous | “subcutaneous injections, 0.05 mg/kg once daily” NCT06512584 ↗ |